MX387817B - Uso de acidos grasos de cadena corta en prevencion de cancer. - Google Patents

Uso de acidos grasos de cadena corta en prevencion de cancer.

Info

Publication number
MX387817B
MX387817B MX2017009532A MX2017009532A MX387817B MX 387817 B MX387817 B MX 387817B MX 2017009532 A MX2017009532 A MX 2017009532A MX 2017009532 A MX2017009532 A MX 2017009532A MX 387817 B MX387817 B MX 387817B
Authority
MX
Mexico
Prior art keywords
compositions
fatty acids
chain fatty
short
cancer prevention
Prior art date
Application number
MX2017009532A
Other languages
English (en)
Other versions
MX2017009532A (es
Inventor
Helena M G P V Reis
Mark A Feitelson
Original Assignee
Univ Temple
Helena Margarida Guerra Pinheiro Vieira Reis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Temple, Helena Margarida Guerra Pinheiro Vieira Reis filed Critical Univ Temple
Publication of MX2017009532A publication Critical patent/MX2017009532A/es
Publication of MX387817B publication Critical patent/MX387817B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Non-Alcoholic Beverages (AREA)

Abstract

La invención se refiere a las composiciones para prevenir o retrasar el inicio del cáncer hepatocelular; las composiciones de la invención pueden comprender ácidos grasos de cadena corta, las composiciones de la invención además pueden comprender una bacteria prebiótica, las composiciones de la invención incluyen composiciones para prevenir o retrasar el inicio de cáncer hepatocelular al tratar o prevenir la inflamación del hígado, enfermedad del hígado y lesiones precancerosas.
MX2017009532A 2015-01-23 2016-01-21 Uso de acidos grasos de cadena corta en prevencion de cancer. MX387817B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562106778P 2015-01-23 2015-01-23
PCT/US2016/014292 WO2016118730A1 (en) 2015-01-23 2016-01-21 Use of short chain fatty acids in cancer prevention

Publications (2)

Publication Number Publication Date
MX2017009532A MX2017009532A (es) 2018-04-10
MX387817B true MX387817B (es) 2025-03-11

Family

ID=56417737

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009532A MX387817B (es) 2015-01-23 2016-01-21 Uso de acidos grasos de cadena corta en prevencion de cancer.

Country Status (12)

Country Link
US (6) US10231941B2 (es)
EP (1) EP3247342B1 (es)
JP (4) JP6783247B2 (es)
KR (1) KR102735818B1 (es)
CN (2) CN107405321A (es)
AU (3) AU2016209244A1 (es)
IL (1) IL253581A0 (es)
MX (1) MX387817B (es)
RU (1) RU2017127597A (es)
SG (2) SG11201705953XA (es)
WO (1) WO2016118730A1 (es)
ZA (1) ZA201704977B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
EP4529950A3 (en) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment
CN113862175A (zh) 2014-12-23 2021-12-31 4D制药研究有限公司 免疫调控
PL3193901T3 (pl) 2014-12-23 2018-10-31 4D Pharma Research Limited Polipeptyd pyrynowy i immunomodulacja
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
PE20180267A1 (es) 2015-06-15 2018-02-06 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
MD3206700T2 (ro) 2015-06-15 2019-12-31 4D Pharma Res Ltd Compoziții conținând tulpini bacteriene
RS59446B1 (sr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Blautia stercosis i wexlerae za upotrebu u lečenju inflamatornih i autoimunskih bolesti
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
WO2017085520A1 (en) 2015-11-20 2017-05-26 4D Pharma Research Limited Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
JP6441536B2 (ja) 2016-03-04 2018-12-19 フォーディー ファーマ ピーエルシー４Ｄ Ｐｈａｒｍａ Ｐｌｃ 細菌株を含む組成物
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
WO2018089861A1 (en) * 2016-11-11 2018-05-17 The Regents Of The University Of California Methods and compositions for the treatment of cancer and metabolic diseases
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
US11065217B2 (en) 2017-01-27 2021-07-20 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
AU2018255269B2 (en) 2017-04-17 2023-03-09 The University Of Chicago Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease
US20220304967A1 (en) * 2017-04-24 2022-09-29 Allerpops Oral microbiota promoting composition cross-reference to related applications
HUE054164T2 (hu) 2017-05-22 2021-08-30 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
WO2018215782A1 (en) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strain
MA49010B1 (fr) 2017-06-14 2020-11-30 4D Pharma Res Ltd Compositions comprenant une souche bactérienne du genre megasphaera et leurs utilisations
SMT202000695T1 (it) 2017-06-14 2021-01-05 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
LT3600363T (lt) 2017-06-14 2021-02-10 4D Pharma Research Limited Kompozicijos, apimančios bakterijų kamienus
AU2018298087A1 (en) 2017-07-05 2020-01-23 Evelo Biosciences, Inc. Compositions and methods of treating cancer using bifidobacterium animalis ssp. lactis
AU2018310705B2 (en) * 2017-08-04 2024-01-18 Societe Des Produits Nestle S.A. Probiotic bacteria preconditioned in a GOS-containing medium and use thereof
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
CN110090230B (zh) * 2018-01-30 2022-07-12 青岛东海药业有限公司 凝结芽孢杆菌在制备预防或治疗胆管癌制剂中的应用
SG11202011031UA (en) * 2018-05-11 2020-12-30 4D Pharma Res Ltd Compositions comprising bacterial strains
SG11202011817WA (en) * 2018-06-01 2020-12-30 Evolve Biosystems Inc Compositions and methods to promote host defense and stimulate, expand, and/or reset t cell repertoires
CA3106315A1 (en) 2018-07-19 2020-01-23 Pendulum Therapeutics, Inc. Methods and compositions for microbial engraftment
WO2021058811A1 (en) * 2019-09-25 2021-04-01 Philipps-Universität Marburg Short-chain fatty acid pentanoate as enhancer for cellular therapy and anti-tumor therapy
KR102510198B1 (ko) * 2019-11-14 2023-03-15 가톨릭대학교 산학협력단 락토바실러스 속 균주 및 SCFA(Short fatty chain acid)를 포함하는 면역 질환의 예방 및 치료용 조성물
TWI734341B (zh) * 2020-01-14 2021-07-21 景岳生物科技股份有限公司 一種副乾酪乳桿菌ｇｍｎｌ-３４６用於抗口腔癌之用途
EP4134089A1 (en) * 2020-03-05 2023-02-15 Liscure Biosciences Co., Ltd. Pharmaceutical composition comprising genus leuconostoc strain as active ingredient for prevention or treatment of cancer
US20240009154A1 (en) * 2020-08-04 2024-01-11 Temple University-Of The Commonwealth System Of Higher Education Methods and compositions for treating cytokine release syndrome
US11938152B2 (en) 2020-08-06 2024-03-26 Kedar N Prasad High-dose antioxidants in cancer treatment
US20240009155A1 (en) * 2020-11-12 2024-01-11 Temple University-Of The Commonwealth System Of Higher Education Use of short chain fatty acids in cancer prevention
WO2022177409A1 (ko) * 2021-02-22 2022-08-25 주식회사 리스큐어바이오사이언시스 류코노스톡 메센테로이데스 균주 유래 나노소포체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학 조성물
GB2631853A (en) * 2022-01-19 2025-01-15 Hodgdon Ian Short-chain fatty acids for cancer treatment
CN117925434B (zh) * 2022-10-26 2025-02-14 慕恩（广州）生物科技有限公司 粪肠球菌mnh 22871及其应用
CN116212027A (zh) * 2023-02-28 2023-06-06 西湖大学 一种调控Treg细胞内铁水平的试剂的用途
WO2025176152A1 (en) * 2024-02-19 2025-08-28 The University Of Hong Kong Probiotics mixtures and methods of use thereof for treating cancers
CN119424400B (zh) * 2024-10-21 2026-03-03 江南大学 缓解衰老的肠道菌群支链氨基酸代谢产物异丁酸和异戊酸及其应用
CN119258047A (zh) * 2024-11-26 2025-01-07 哈尔滨医科大学 琥珀酸在制备防治肝癌药物中的新用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735967A (en) 1985-05-28 1988-04-05 Neesby Torben E Method for desensitizing the gastrointestinal tract from food allergies
AU645070B2 (en) 1990-04-10 1994-01-06 Nb International Technologies Use of short chain fatty acid containing lipids to maintain gastrointestinal integrity and function in patients DO NOT SEAL - SEE LETTER DATED 22.03.94
PH31403A (en) 1991-03-01 1998-10-29 Warner Lambert Co Therapeutic compositions to protect and recuscitate mammalian cells and methods for preparing same.
AU696167B2 (en) 1993-10-29 1998-09-03 Trustees Of Boston University Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
JP2000072667A (ja) 1998-08-25 2000-03-07 Kurasuraa:Kk 大腸炎治療用経口投与剤
US6201077B1 (en) 1998-12-01 2001-03-13 Phillips Petroleum Company Process that produces polymers
EP1034788A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactic acid bacteria strains capable of preventing diarrhea
WO2003057730A1 (en) 2002-01-07 2003-07-17 Euroscreen S.A. Ligand for g-protein coupled receptor gpr43 and uses thereof
AU2003213684C1 (en) 2002-03-04 2008-10-23 Merck Hdac Research, Llc Methods of inducing terminal differentiation
CN100566711C (zh) 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
US8846039B2 (en) 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
BR0314112A (pt) 2002-09-13 2005-07-12 Univ Virginia Commonwealth Combinação de a) n-{5-[4-(4-metil-piperazino-metil)-benzoilamido]-2-metil fenil}-4-(3-piridil)-2-pirimidina-amina e b) um inibidor de desacetilase de histona para o tratamento de leucemia
US20050023179A1 (en) 2003-07-31 2005-02-03 Albritton Charles Wade Fragile-product cage for vacuum packaging appliances
CA2535889A1 (en) 2003-08-29 2005-03-17 Aton Pharma, Inc. Combination methods of treating cancer
WO2007016955A1 (en) 2005-07-29 2007-02-15 Matuschka-Greiffenclau Markus Alcohol metabolism moderating composition
CA2647986C (en) * 2006-03-31 2014-07-08 Erasmus University Medical Center Rotterdam Compositions for tumor growth control
WO2008054293A1 (en) * 2006-11-03 2008-05-08 Salutary Care Limited Composition, its use for treating systemic diseases a conditions, and product containing said composition
US20080153908A1 (en) 2006-12-20 2008-06-26 Jani Dharmendra M Method of Treating Mucin Deficiency with an Active Pharmaceutical and Related Composition
EP2237684A2 (en) 2008-01-08 2010-10-13 Akthelia Pharmaceuticals Agonists for antimicrobial peptide systems
CN101214234B (zh) * 2008-01-10 2010-09-08 中国人民解放军第二军医大学 α-羟基酸在制备癌瘤体内注射治疗药物中的应用
WO2010095950A1 (en) 2009-02-18 2010-08-26 Sea Qiq As Mixture of inorganic compounds, preparations containing the mixture and use of the mixture
EP2808024B1 (en) 2009-06-19 2019-04-24 DuPont Nutrition Biosciences ApS Bifidobacteria for treating congestive heart failure
US8962686B2 (en) 2010-04-28 2015-02-24 The Chinese University Of Hong Kong Method and medication for prevention and treatment of ocular hypertension and glaucoma
EP2389932A1 (en) 2010-05-28 2011-11-30 Lunamed AG Compositions for use in genetic disorders comprising 4-phenyl-butyric acid and its salts
EP2616051A1 (en) 2010-07-29 2013-07-24 Cosmo Technologies Ltd. Pharmaceutical and/or dietary compositions based on short chain fatty acids
WO2012074351A1 (en) 2010-11-29 2012-06-07 Universiti Putra Malaysia Tumour cytotoxic agent and methods thereof
WO2012118535A1 (en) * 2011-03-01 2012-09-07 Quorum Innovations, Llc Materials and methods for treating conditions associated with pathogenic biofilm
WO2012131069A1 (en) 2011-03-31 2012-10-04 Proponent Biotech Gmbh Short chain fatty acids and their derivatives for use in treatment immunogenic disorders
US9402820B2 (en) * 2011-04-22 2016-08-02 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of pyruvate or succinate to enhance the efficacy of a hypoxia activated prodrug for the treatment of tumors
KR20220042485A (ko) 2012-01-16 2022-04-05 엘라자베스 맥켄나 간 질환들 및 장애들의 치료를 위한 조성물들 및 방법들
GB201215289D0 (en) 2012-08-28 2012-10-10 Medical Res Council Nanoparticle formulation
TWI463986B (zh) 2012-08-29 2014-12-11 Univ China Medical 胚芽乳酸桿菌ｃｍｕ９９５菌株之新用途
WO2015006355A2 (en) 2013-07-09 2015-01-15 Puretech Ventures, Llc Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease
WO2015021936A1 (en) 2013-08-16 2015-02-19 The University Of Hong Kong Method and compositions for treating cancer using probiotics cross-reference to related application

Also Published As

Publication number Publication date
CN115350171A (zh) 2022-11-18
US20240342122A1 (en) 2024-10-17
KR20170128247A (ko) 2017-11-22
US11963938B2 (en) 2024-04-23
AU2016209244A1 (en) 2017-08-17
JP2025038120A (ja) 2025-03-18
RU2017127597A3 (es) 2019-07-17
KR102735818B1 (ko) 2024-11-28
EP3247342A1 (en) 2017-11-29
CA2974510A1 (en) 2016-07-28
US10143669B2 (en) 2018-12-04
US20190160031A1 (en) 2019-05-30
JP2018504457A (ja) 2018-02-15
US20250213508A1 (en) 2025-07-03
MX2017009532A (es) 2018-04-10
AU2019201799B2 (en) 2020-10-15
US10231941B2 (en) 2019-03-19
AU2020239699A1 (en) 2020-10-15
EP3247342A4 (en) 2018-10-10
IL253581A0 (en) 2017-09-28
JP2023027219A (ja) 2023-03-01
WO2016118730A1 (en) 2016-07-28
ZA201704977B (en) 2022-12-21
CN107405321A (zh) 2017-11-28
US20220008369A1 (en) 2022-01-13
SG10201907660YA (en) 2019-10-30
JP6783247B2 (ja) 2020-11-11
US20180008565A1 (en) 2018-01-11
JP2021020929A (ja) 2021-02-18
US20180185307A1 (en) 2018-07-05
RU2017127597A (ru) 2019-02-25
SG11201705953XA (en) 2017-08-30
EP3247342B1 (en) 2026-01-07
AU2019201799A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
MX387817B (es) Uso de acidos grasos de cadena corta en prevencion de cancer.
PH12021550756A1 (en) Compositions and methods for treating and/or preventing cardiovascular disease
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
MX2022012374A (es) Composiciones multi-suplementos.
WO2014062720A3 (en) Methods of treating cancer
MX383164B (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
MX2017011822A (es) Anticuerpos anti-muc16 y sus usos.
PH12018500659A1 (en) Compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof
EP4299122A3 (en) Compositions and methods for treating skin and mucous membrane diseases
MX2017001971A (es) Composiciones antimetanogenicas y sus usos.
HK1220155A1 (zh) 治疗癌症的方法
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX394452B (es) Inhibicion de la actividad de olig2.
TR201908639T4 (tr) Dejeneratif göz bozukluklarının önlenmesi ve veya tedavisine yönelik safran bazlı bileşimler.
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
AU2015267160A8 (en) Methods and compositions for preventing ischemia reperfusion injury in organs
MX384259B (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
HK1256753A1 (zh) 芳基-取代的二氢喹诺酮、它们的制备和它们作为药物的用途
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
MX2016012244A (es) Compuestos y sus metodos de uso.
PH12017500203B1 (en) Nutritional composition for use in promoting gut and/or liver maturation and/or repair
MX383947B (es) Composiciones de colágeno 7 y métodos para usar las mismas.
SI3097921T1 (sl) Sestavki, ki obsegajo geraniol in suh ingver za uporabo pri zdravljenju sindroma razdražljivega črevesja